Sanofi - Aventis Groupe: Second positive Phase 3 Dupixent (d

Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase

Related Keywords

Japan , United States , Paris , France General , France , America , Eva Schaefer Jansen , Arnaud Delepine , Felix Lauscher , Georged Yancopoulos , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Sally Bain , Naimish Patel , Exchange Commission , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Head Of Global Development , Dupilumab Development Program , Teva Pharmaceutical Industries Ltd , Global Development , Chief Scientific Officer , Worst Itch Numeric Rating Scale , Global Assessment , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Digital Media , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Sanofi , Eventis , Roupe , Second , Positive , Hase , Dupixent , Dupilumab , Trial , Onfirms , Significant , Improvements , Patients , Prurigo , Nodularis ,